We all want to be happy, so why are we so drawn to negative and bad news and why does it stir something up inside of us? Is it because bad news is an obstacle to our happiness, and we […]
ARMO Biosciences (ARMO) listed in January 2018 at $17 per share. The company had a phase III pancreatic cancer drug in AMO010, a recombinant form of human interleukin 10 (IL-10). There is no effective drug to treat pancreatic cancer. AMO010 […]
Eiger Biopharmaceuticals (NASDAQ:EIGR), a company developing treatment for rare diseases, which often are reimbursed at a premium price, published a study on April 24, 2018, indicating the effectiveness of its drug, lonafarnib, to treat Hutchinson-Gilford Progeria Syndrome (HGPS). The disease […]
MyoKardia (NASDAQ:MYOK), a leading precision cardiovascular medicine company, reported good data during 2015-16 on its drug, mavacamten, to treat hypertrophic cardiomyopathy (HCM), a condition that reduces the rate of heart contractions because of the thickening of surrounding heart muscles. Mavacamten, […]
Dynavax’s (NASDAQ:DVAX) BLA application for its Hepatitis B vaccine first received a complete response letter from the FDA in 2013 and then experienced further regulatory delays between 2015-2016. Some of the FDA requests involved the vaccine’s overall immunogenicity data, while […]